Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.

International Journal of Clinical Practice
Yoshimasa AsoIsao Usui

Abstract

Soluble dipeptidyl peptidase-4 (sDPP-4) is secreted by hepatocytes and induces adipose tissue inflammation and insulin resistance. Sodium-glucose co-transporter-2 (SGLT2) inhibitors can improve hepatic steatosis by inhibiting hepatic de novo lipogenesis. We investigated the effects of dapagliflozin (an SGLT2 inhibitor) on serum levels of sDPP-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Fifty-seven patients with type 2 diabetes and NAFLD were randomized to a dapagliflozin group (5 mg/d for 24 weeks) (n = 33) or the control group (n = 24). Serum levels of sDPP-4 were measured with a commercial ELISA kit. Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) areas were measured by dual bioelectrical impedance analysis. In a total of 57 patients, baseline serum sDPP-4 was positively correlated with aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transferase (GGT) and HOMA-IR Both VAT and SAT areas decreased significantly in the dapagliflozin group alone. Liver enzymes were decreased at 24 weeks in the dapagliflozin group, but were unchanged in the control group. Although both groups showed significant reduction of serum sDPP-4 after 24 weeks of treatme...Continue Reading

References

Apr 19, 2002·The New England Journal of Medicine·Paul Angulo
Aug 2, 2003·Critical Reviews in Clinical Laboratory Sciences·Anne-Marie LambeirIngrid De Meester
Jun 15, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Joel C Marrs, Joseph J Saseen
Sep 22, 2009·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Jeong-Hoon LeeHyo-Suk Lee
Sep 28, 2010·European Journal of Clinical Investigation·Norma I RallónJosé M Benito
Dec 4, 2010·International Journal of Cancer. Journal International Du Cancer·Judith ErtleAli Canbay
Mar 17, 2011·Advances in Clinical Chemistry·Kei OhnumaChikao Morimoto
Jun 30, 2012·The Journal of Clinical Endocrinology and Metabolism·Antoine MakdissiParesh Dandona
Sep 24, 2014·Drug Design, Development and Therapy·Michael A Nauck
Oct 29, 2015·Diabetes Research and Clinical Practice·Yoshimasa AsoToshihiko Inukai
Oct 17, 2017·Molecular Metabolism·Christian BaumeierAnnette Schürmann
Nov 21, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Tracey G SimonAndrew T Chan
May 10, 2018·Nature Reviews. Gastroenterology & Hepatology·Susanne SchusterAriel E Feldstein

❮ Previous
Next ❯

Citations

Sep 4, 2019·Obesity·Matthias Blüher
Apr 2, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Aline David-SilvaUbiratan Fabres Machado
May 9, 2019·International Journal of Molecular Sciences·Hamza El HadiMarco Rossato
Jun 26, 2020·Clinical and Translational Science·Suzanna L AttiaMarialena Mouzaki
Jul 27, 2020·Endocrinology, Diabetes & Metabolism·Vasiliki Mittag-RoussouCaroline S Stokes
Mar 11, 2020·Frontiers in Endocrinology·Chelsea S Pan, Takara L Stanley
Jul 30, 2020·Nature Communications·Laurie L BaggioDaniel J Drucker
Oct 4, 2020·Diabetes/metabolism Research and Reviews·Francisca Dos Santos CoelhoAdelino Leite-Moreira
Nov 28, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Mario Simental-MendíaLuis E Simental-Mendía
Jan 14, 2021·Journal of Gastroenterology and Hepatology·Lampros ChrysavgisEvangelos Cholongitas
Oct 30, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Lin ChenDongmei Zheng
Feb 18, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Hiroaki Seino
Mar 9, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Yi KuangMin Ye
Aug 20, 2020·Vascular Pharmacology·Yingxiu KangXiaoxiao Song
Apr 23, 2021·Expert Review of Clinical Pharmacology·Elizabeth M LamosStephen N Davis
Jun 16, 2021·Journal of Gastroenterology and Hepatology·Susrichit PhrueksotsaiSatawat Thongsawat
Sep 12, 2021·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Manqiu MoNing Xia
Oct 5, 2021·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Cheng Han NgMark Muthiah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.